Shellback Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Shellback Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,384	Closed	-$5.7M	–	106
2025 Q4	$5.7M	Buy	+7,384	New	+$5.01M	0.54%	50

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Shellback Capital's REGN Position: Q1 2026 in Review

Shellback Capital sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 7,384 shares — an estimated $5.7M sold.

Shellback Capital first reported a position in REGN in Q4 2025 and held it in 1 quarter. The position peaked at $5.7M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Shellback Capital reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Shellback Capital sold 7,384 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $5.7M.
Shellback Capital first reported a position in Regeneron Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Shellback Capital's Regeneron Pharmaceuticals position peaked at $5.7M in Q4 2025.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Shellback Capital's 13F filing for Q1 2026, filed 15 May 2026.